Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$13.45 USD
-1.18 (-8.07%)
Updated May 17, 2024 04:00 PM ET
After-Market: $13.42 -0.03 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
VRDN 13.45 -1.18(-8.07%)
Will VRDN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Other News for VRDN
Viridian Therapeutics (VRDN) Gets a Buy from Stifel Nicolaus
Buy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion Potential
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
Viridian Therapeutics price target lowered by $5 at Oppenheimer, here's why